Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.
The report provides a detailed understanding and analysis of how and why companies enter stem cell deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 530 stem cell deals announced since 2010 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of stem cell dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in stem cell dealmaking since 2010.
Chapter 3 provides an overview of the leading stem cell deals since 2010. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of stem cell deals signed and announced since Jan 2010, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2010.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- Understand deal trends since 2010
- Browse stem cell collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
The report provides a detailed understanding and analysis of how and why companies enter stem cell deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 530 stem cell deals announced since 2010 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of stem cell dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in stem cell dealmaking since 2010.
Chapter 3 provides an overview of the leading stem cell deals since 2010. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of stem cell deals signed and announced since Jan 2010, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2010.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report Scope
Stem Cell Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of stem cell trends and structure of deals entered into by leading biopharma companies worldwide.Stem Cell Collaboration and Licensing Deals includes:
- Trends in stem cell dealmaking in the biopharma industry
- Directory of stem cell deal records covering pharmaceutical and biotechnology
- The leading stem cell deals by value
- Most active stem cell licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Stem cell dealmaking by technology type
Chapter 2 - Trends in stem cell dealmaking
Chapter 3 - Leading stem cell deals
Chapter 4 - Most active stem cell dealmakers
Chapter 5 - Stem cell contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A*STAR Agency for Science
- Technology and Research
- A*STAR Genome Institute of Singapore
- Aastrom Biosciences
- ABT Holding Company
- Abu Dhabi Stem Cells Center
- Accelerated Biosciences
- Accellta
- Access BIO
- Access Pharmaceuticals
- ACEA Biosciences
- Actinium Pharmaceuticals
- Admedus
- AdnaGen
- Advanced BioScience Laboratories
- Advanced Cell Technology
- Aelan Cell Technologies
- Affomix
- AGC Asahi Glass
- Ageless Biotech
- Ageless Regenerative
- AgeX Therapeutics
- Agilent Technologies
- AiVita Biomedical
- Akadeum Life Sciences
- Albert Einstein College of Medicine
- Alkem Laboratories
- Allele Biotechnology and Pharmaceuticals
- AlloSource
- ALS Therapy Development Institute
- Amedica
- American CryoStem
- American Society of Hematology
- American Type Culture Collection (ATCC)
- Amgen
- Angel Biotechnology
- Angioblast Systems
- Angiocrine Bioscience
- Angionetics
- Angiostem
- Anthony Nolan
- Antitope
- Apceth
- Aratana Therapeutics
- Arbor Biotechnologies
- Ariana Pharma
- Array Biopharma
- Arteriocyte Medical Systems
- Arthrex
- Ascendance Biotechnology
- Astellas Pharma
- Asterand Bioscience
- Asterias Biotherapeutics
- AstraZeneca
- ATEC Spine
- Athersys
- ATMI LifeSciences
- Australian Research Council
- AuxoCell Laboratories
- Axcelead Drug Discovery Partners
- Axiogenesis
- AXM Pharma
- AxoSim
- Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences
- Barbara Ann Karmanos Cancer Institute
- Bayer Innovation
- Bayer Schering Pharma
- Baylor Research Institute
- BD Biosciences
- Beckman Research Institute of City of Hope
- Becton Dickinson
- Beijing Genomics Institute (BGI)
- Berlin-Brandenburg Center for Regenerative Therapies
- Be The Match BioTherapies
- Bill and Melinda Gates Foundation
- Bio-Techne
- BioCardia
- Biocompatibles International
- Biocrates
- Biocrea
- BioDlogics
- BioEclipse Therapeutics
- Biogalenys
- Biogen
- BioHeart
- Biokine Therapeutics
- BioLamina
- BiolineRX
- Biological Industries
- Biomed
- Biomodels
- Bioneer
- BioPontis Alliance
- bioRASI
- BioRestorative Therapies
- BioSante Pharmaceuticals
- Biotech Products Services & Research
- BlueRock Therapeutics
- Boehringer Ingelheim
- Bone Therapeutics
- BrainStorm Cell Therapeutics
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Caladrius Biosciences
- Calidi Biotherapeutics
- California Institute for Regenerative Medicine
- California Stem Cell
- Calimmune
- Canadian Institutes of Health Research
- CareDx
- Case Western Reserve University
- Case Western Reserve University School of Medicine
- CASI Pharmaceuticals
- Catalent
- Cedars-Sinai Medical Center
- CeeTox
- Celgene
- Cell2in
- Cell Care Therapeutics
- Cell Cure Neurosciences
- Cellect Biotechnology
- Cellectis
- Cellectis Bioresearch
- Cellectricon
- Cellerix
- Celling Biosciences
- CellProThera
- Celltex Therapeutics
- Cell Therapy Catapult
- Cellular Biomedicine
- Cellular Dynamics International
- Cellzome
- Celsis In Vitro Technologies
- Celulas Genetica
- Censo Biotechnologies
- Center for iPS Cells Research and Application
- Centogene
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Centre for Drug Research and Development (CDRD)
- Cephalon
- Cesca Therapeutics
- CFD Research
- CHA Bio & Diostech
- Charite-Universitatsmedizin
- ChemDiv
- Chemizon
- Children's Hospital Boston
- Children's Hospital of Orange County
- Children's Research Institute
- China Cord Blood
- China PharmaHub
- China Southeast University
- Chong Kun Dang
- Cincinnati Children’s Hospital Medical Center
- Cipla
- Citius Pharmaceuticals
- City of Hope
- Cleveland BioLabs
- Cleveland Clinic
- Cleveland Cord Blood Center
- Clontech Laboratories
- CNA Development
- COARE Biotechnology
- Cognate BioServices
- Cohen-McNiece Foundation
- Columbia University
- Cord Blood America
- Cordlife
- CordVida
- Cornell University
- Corning
- CPC Clinical Research
- Creative Medical Technologies
- CRISPR Therapeutics
- CropLife America
- Crown Bioscience
- Cryo-Cell International
- CSIRO
- Curasan
- CvergenX
- Cynata Therapeutics
- Cystinosis Research Foundation
- Cytomedix
- CytoMed Therapeutics
- Cytori Therapeutics
- CYTOVIA Therapeutics
- Cytovis
- Dako
- Dana-Farber Cancer Institute
- Deepcell
- DefiniGEN
- Department of Defense
- Department of Health and Human Services
- DePuy
- Dexterity
- DiNonA
- Dolomite
- Dow Chemical
- Dow Corning
- Duke University
- DV Biologics
- Ectycell
- EdiGene
- Eli Lilly
- Elixirgen
- EMD Millipore
- Emerging Healthcare Solutions
- ENCell
- Entest BioMedical
- Epistem
- Eppendorf
- ERS Genomics
- ES Cell International
- Eterna Therapeutics
- Ethos Discovery
- European Commission
- European Union
- Eutilogics
- Evotec
- ExCellThera
- Exploit Technologies
- ExxonMobil
- Fast Forward
- Fate Therapeutics
- Federal Ministry of Education and Research (BMBF)
- Florey Institute of Neuroscience and Mental Heath
- Florica Therapeutics
- Florida State University
- Fluidigm
- Fondazione San Raffaele
- Fondazione Telethon
- Food and Drug Administration (FDA)
- Fortis Healthcare
- Fraunhofer Institute for Molecular Ecology (IME)
- Fred Hutchinson Cancer Research Center
- Fujifilm
- FUJIFILM Cellular Dynamics
- Fundacio Clinic
- Fusion Antibodies
- Gallant Therapeutics
- Gamida Cell
- GE Healthcare
- GenCure
- Generex Biotechnology
- Genezen
- Genome Diagnostics
- genOway
- Gentium
- GenVec
- Geron
- Gladstone Institutes
- GliaMed
- Global Alliance for Innovation in Neuroscience
- Golden Helix
- Golden Meditech
- Government of United Kingdom
- Grandhope Biotech
- Griffith University
- GSK
- Guangzhou Municipality Tianhe Nuoya Bio-engineering
- Hadasit Bioholdings
- Hadasit Medical Research Services and Development
- Hadassah Medical Center
- Hadassah University
- Haihe Laboratory of Cell Ecosystem
- Hamad Bin Khalifa University
- Hamilton Thorne
- Hamner Institutes for Health Sciences
- Harvard Medical School
- Harvard Stem Cell Institute
- Harvard University
- Healios K.K.
- Healthpoint
- Heartseed
- Heat Biologics
- Hemogenix
- Hemostemix
- HepaTx
- Heraeus
- Histogen
- Hoffmann La Roche
- Hong Kong Baptist University
- Horizon Discovery
- Hospital for Sick Children
- Huapont Pharma
- Hubrecht Institute
- Humacyte
- Human Life CORD Japan
- Human Longevity
- Humex Medical
- iCo Therapeutics
- ID Pharma
- Ilika Technologies
- Illumina
- ImageIQ
- ImmuneRegen BioSciences
- Immunis
- ImmunityBio
- ImmunoCellular Therapeutics
- Implant Therapeutics
- Indiana University
- Indian Immunological
- Innovation Australia Research and Development
- Innovative Medicines Initiative (IMI)
- Insitro
- Instem
- Institute of Cancer Research
- Institute Of Molecular Biotechnology
- Integrated Biobank of Luxembourg
- Intellia Therapeutics
- IntelliCell BioSciences
- Intercytex
- International Stem Cell
- Intrexon
- Invitrx Therapeutics
- InVivo Therapeutics
- Ionis Pharmaceuticals
- iPS Academia Japan
- ISee3D
- Israeli National Authority for Technological Innovation
- Jadi Cell
- Jain Foundation
- Janssen Biotech
- Japan Science and Technology Agency
- Jasper Therapeutics
- Jazz Pharmaceuticals
- JCR Pharmaceuticals
- Jian An Pharmaceuticals
- Johns Hopkins University
- Johnson & Johnson Innovation
- Juvenile Diabetes Research Foundation
- Keck School of Medicine of USC
- KellBenx
- Kempbio
- Kensey Nash
- Kiadis Pharma
- Kings College London
- Kite Pharma
- Kumamoto University
- Kyoto Biken
- Kyoto University
- Lab21
- Laboratory Corporation of America
- La Jolla Pharmaceutical
- Lee Moffitt Cancer Center
- Lehigh University
- Leiden University
- Lentigen
- Leona M and Harry B Helmsley Charitable Trust
- Leukemia & Lymphoma Society
- Life Technologies
- Life Technologies Corporation
- Lineage Cell Therapeutics
- Longeveron
- Lonza
- Loughborough University
- Lucigen
- Lucy Biotech
- Lupus Foundation of America (LFA)
- Macquarie University
- Magenta Therapeutics
- Maryland Stem Cell Research Fund
- Maryland Technology Development Corporation
- Massachusetts General Hospital
- Matricel
- Maxcyte
- Mayo Clinic
- McEwen Centre for Regenerative Medicine
- McGill University
- MD Anderson Cancer Center
- Medac
- Medexus Pharmaceuticals
- Medical College of Wisconsin
- Medical Research Council
- Medical University South Carolina
- Medistem
- Mekonos
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Merus
- Mesoblast
- Metrion Biosciences
- Michael J Fox Foundation
- Midas Mediscience
- Miltenyi Biotec
- Minerva Biotechnologies
- Ministry of Industry and Trade of the Russian Federation
- Miracle Babies
- Miragen Therapeutics
- Mirna Therapeutics
- Mokshagundam Biotechnologies
- Molecular Imaging Research
- Molecular Templates
- Monash University
- Montreal Heart Institute
- MPI Research
- Multiclonal Therapeutics
- Munich Technical University
- Murdoch Childrens Research Institute
- myTomorrows
- NanoCellect Biomedica
- Nano Dimension
- nanoRanch
- Nanotope
- NantKwest
- Nanyang Technological University
- National Cancer Institute
- National Center for Advancing Translational Sciences (NCATS)
- National Center for Regenerative Medicine
- National Eye Institute
- National Health and Medical Research Council
- National Heart
- Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Biomedical Innovation
- National Institute on Aging
- National Institutes of Health
- National Institutes of Health Center for Regenerative Medicine
- National Psoriasis Foundation
- National Research Council Industrial Research Assistance Program
- National Science Foundation
- National Stem Cell Foundation
- National University of Ireland
- Galway (NUI Galway)
- Ncardia
- Netherlands Government
- NeuralStem
- Neural Stem Cell Institute
- Neusentis
- Northwestern University
- Novartis
- Novellus Therapeutics
- Novo Nordisk
- Nuclea Biotechnologies
- NuPotential
- NuVasive
- Nvidia
- Obagi Medical Products
- Ocata Therapeutics
- OcellO
- Octane Biotech
- Ocumension Therapeutics
- Omeros
- OncoImmune
- OncoMed Pharmaceuticals
- OptoRobotix
- Orbsen Therapeutics
- Orchard Therapeutics
- Oregon Health Sciences University
- Organovo
- Orgenesis
- ORIG3N
- Orthocell
- OrthoCyte
- Orthopaedic Research and Education Foundation
- Osiris Therapeutics
- Oxford Biodynamics
- Parcell Laboratories
- Parcell Spine
- Pathways to Stem Cell Science
- PAWS Pet Company
- PerkinElmer
- Pfizer
- PharmaCell
- PharmaCyte Biotech
- Philogen
- Pikamab
- Plasticell
- Platelet BioGenesis
- Pluriomics
- Pluristem Therapeutics
- Pluristyx
- Polyplus Transfection
- PreCerv
- Primera Bioscience Research
- Princess Margaret Hospital
- Pro-Cure Therapeutics
- ProBioGen
- Procella Therapeutics
- Procyon Technologies
- Progenitor Cell Therapy
- Promega
- Promosome
- Protein Genomics
- Proteonomix
- P T Kalbe Farma
- Pulthera
- QIAGEN
- Q Therapeutics
- Quintiles
- RainDance Technologies
- Ramot at Tel Aviv University
- R Biomedical
- RecipharmCobra Biologics
- Recopharma
- ReCyte Therapeutics
- Regen BioPharma
- Regenerative Sciences
- Regenerex
- Regenetech
- Regeneus
- Reinnervate
- ReNeuron
- Renovacare
- RenovoCyte
- ReproCell
- Research Products Development Company
- RHEI Pharmaceuticals
- RNL Bio
- Roche
- Roche Applied Science
- Rockefeller University
- Rohto Pharmaceutical
- Roslin Cellab
- Roslin Cells
- Roslin Institute
- Royal Children’s Hospital
- Royal College of Surgeons (Ireland)
- RST Biomedikal Sanayi
- RTI Surgical
- Rubedo Life Sciences
- Rutgers University
- RxBio
- Salk Institute
- Sana Biotechnology
- SanBio
- Sanford Burnham Institute
- Sanford Consortium for Regenerative Medicine
- Sangamo Therapeutics
- Sankara Nethralaya
- Sanofi
- Sanofi-Aventis
- San Raffaele Telethon Institute for Gene Therapy
- Scaled Biolabs
- Schepens Eye Research Institute
- SCM Pharma
- ScreenCell
- Scripps Genomic Medicine
- Seattle Childrens Research Institute
- Selexis
- SeqWright
- Seres Therapeutics
- Service Francophone du Sang
- Shanghai Cell Therapy Group
- Shanghai Jia Fu Medical Apparatus
- Sharp Edge Labs
- Shenogen Pharma
- Shoreline Biosciences
- Shrink Chips
- Shrink Nanotechnologies
- Sigma-Aldrich
- Sigma-Tau
- Sigma Life Science
- SimonMed Imaging
- Sirion Biotech
- Sirius Genomics
- Sirona Biochem
- Sistemic
- Sitoa
- Smartwise
- Smith & Nephew
- South Texas Blood & Tissue Center
- Spectrum Pharmaceuticals
- Spinogenix
- Stanford University
- Stellar Pharmaceuticals
- StemBioSys
- StemCardia
- Stem Cell & Regenerative Medicine International (SCRMI)
- Stem Cell Medicine
- StemCells
- Stem Cells 21
- StemCell Systems
- Stemcell Technologies
- Stem Cell Therapeutics
- StemCyte
- Stemedica Asia
- Stemedica Cell Technologies
- Stem Genomics
- Stemina Biomarker Discovery
- Stemnion
- Stempeutics
- Steven M. Schwartzberg Memorial Fund
- Stryker
- Suneva Medical
- Superview Biotechnology
- Swedish Orphan Biovitrum
- SwitchGear Genomics
- Synterys
- System Biosciences
- Taconic Biosciences
- TaiRx
- Takara Bio
- Takeda Pharmaceutical
- TAP Biosystems
- Targazyme
- Taxus Cardium Pharmaceuticals
- Technology Strategy Board (UK)
- Technology University Dresden
- Teijin
- Temple University
- Terumo Blood and Cell Technologies
- TET Systems
- Teva Pharmaceutical Industries
- The Automation Partnership
- The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC)
- The New York Stem Cell Foundation
- TheraBiologics
- Theragent
- Therakine
- Therapeutic Solutions International
- The Regents of the University of California
- ThermoGenesis
- The UK Stem Cell Bank
- Thomas Jefferson University
- Thrive Bioscience
- TiGenix
- Tissue Genesis
- Tissue Regeneration Therapeutics (TRT)
- Tiziana Life Sciences
- TONIX Pharmaceuticals
- Transgenomic
- Transposagen Biopharmaceuticals
- TreeFrog Therapeutics
- Trestle Biotherapeutics
- Trillium Therapeutics
- Tri Phuoc
- TTFactor
- Tu Dresden
- U CAN-CER VIVE Foundation
- UCB
- Unilever
- University Ann & Robert H. Lurie Children’s Hospital
- University Campus Suffolk
- University City Science Center
- University College London
- University Health Network
- University Hospitals Case Medical Center
- University of Adelaide
- University of Birmingham
- University of California
- University of California
- Davis
- University of California
- San Diego
- University of California
- San Diego (UCSD) School of Medicine
- University of California Irvine
- University of California Los Angeles
- University of California San Francisco
- University of Cambridge
- University of Cologne
- University of Dundee
- University of Edinburgh
- University of Florida
- University of Louisville
- University of Maryland
- University of Maryland School of Medicine
- University of Massachusetts
- University of Massachusetts
- Amherst
- University of Massachusetts Medical School
- University of Medicine and Dentistry of New Jersey (UMDNJ)
- University of Melbourne
- University of Miami Miller School of Medicine
- University of Michigan
- University of Minnesota
- University of Montreal Pharmacogenomics Centre
- University of Notre of Dame
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Pittsburgh Medical Center
- University of Queensland
- University of Rochester Medical Center
- University of Sheffield
- University of South Carolina
- University of Southern California
- University of Sydney
- University of Tokyo
- University of Tubingen
- University of Utah
- University of Washington
- University of Wisconsin-Madison
- University of York
- US Government
- US Spine
- US Stem Cell Clinic
- Vascugen
- Vatican
- Vectalys
- Vertex Pharmaceuticals
- Vet-Stem
- ViaCord
- ViaCyte
- Virdante Biophrmaceuticals
- Viscofan BioEngineering
- VistaGen Therapeutics
- VitaThreads
- Vitro Diagnostics
- Vitrolife
- Vivalis
- Vivo Biosciences
- Vor Biopharma
- Wake Forest University
- WCTE
- Weill Cornell Medical College
- Wellcome Trust
- Wellcome Trust Sanger Institute
- W L Gore
- Worcester Polytechnic Institute (WPI)
- Yale University
- Yeda Research and Development Company
- Yorkshire Cancer Research
- Yumanity Therapeutics
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
